Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a shared antigen linking CD4<sup>+</sup> T and B cell pathology in Sjögren's disease.

Science advances·2026
Same author

Distinct roles of STAT3 and STAT5 in CAR T cell therapy.

Molecular therapy. Oncology·2026
Same author

[Strategies to overcome CAR-T cell exhaustion and terminal differentiation].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

CD28-driven ex vivo generation of stem-like memory CD8<sup>+</sup> T cells bypassing CD3/TCR signaling.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-cell Efficacy and Lowers Systemic Toxicity.

Cancer immunology research·2026
Same author

[Novel cancer immunotherapy using cell-derived membrane vesicles loaded with multiple immunomodulatory factors].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Related Experiment Video

Updated: Sep 2, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

772

[Development of universal CAR-T cells].

Yuki Kagoya1,2, Naoto Hirano3,4

  • 1Division of Immune Response, Aichi Cancer Center Research Institute.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|August 4, 2022
PubMed
Summary

Universal CAR-T cells offer off-the-shelf cancer immunotherapy by using healthy donor T cells. This review summarizes trials and discusses challenges like persistence and genetic stability for broader application.

Keywords:
Chimeric antigen receptorGenome editingHuman leukocyte antigenT cell

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.6K

Related Experiment Videos

Last Updated: Sep 2, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

772
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.6K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy is effective for B-cell malignancies.
  • Patient-derived CAR-T cells face challenges of high cost and variable quality, limiting use in solid tumors.
  • Allogeneic, or universal, CAR-T cells from healthy donors offer a potential solution.

Purpose of the Study:

  • To review recent clinical trials of universal CAR-T cells.
  • To discuss strategies for overcoming challenges in universal CAR-T cell therapy.
  • To explore the future potential of off-the-shelf CAR-T cell immunotherapy.

Main Methods:

  • Review of current clinical trial data on universal CAR-T cells.
  • Analysis of challenges including T-cell receptor and HLA ablation.
  • Discussion of CAR-T cell persistence and genome editing safety concerns.

Main Results:

  • Universal CAR-T cells show promise for allogeneic adoptive immunotherapy.
  • Challenges such as limited persistence and potential chromosomal abnormalities persist.
  • Ongoing research aims to enhance the efficacy and safety of universal CAR-T cells.

Conclusions:

  • Universal CAR-T cells represent a significant advancement towards accessible, off-the-shelf cancer immunotherapy.
  • Addressing issues of T-cell persistence and genomic integrity is crucial for clinical success.
  • Further development is needed to expand the application of universal CAR-T cells to diverse cancer types.